Elevance Health, Inc.
ELV
$424.24
+1.32%
Elevance Health, Inc. is one of the largest health insurers in the United States, providing medical benefits to approximately 45 million members across employer, individual, and government-sponsored plans, and operating as the largest single licensee of the Blue Cross Blue Shield brand in 14 states. The company is distinct in its dual-engine model: a massive Health Benefits segment (roughly $42.7 billion in quarterly revenue) complemented by Carelon, a fast-growing healthcare services and pharmacy benefit management platform generating about $19.2 billion. The current investor narrative centers on the durability of government-sponsored programs (Medicaid and Medicare Advantage) following a larger-than-expected 2027 CMS payment rate increase, which lifted sentiment across managed care in April 2026. At the same time, debate persists around medical cost trends, the sustainability of Carelon's margin contribution, and whether Elevance can translate revenue growth into consistent bottom-line expansion after a volatile 2025 earnings cadence.…
ELV
Elevance Health, Inc.
$424.24
Investment Opinion: Should I buy ELV Today?
The synthesized recommendation for Elevance Health is a Hold, reflecting a balanced view of its deep valuation discount and strong analyst support against stagnant revenue growth and margin compression. The consensus analyst rating is 'Buy' with a mean of 1.77, and the average target price of $450.05 implies a modest 7.5% upside from the current $418.72. While the company's 45 million members and dual-engine model provide stability, the lack of top-line growth and declining profitability warrant caution until clearer signs of margin recovery emerge.
Supporting evidence for the Hold rating includes the attractive valuation: a trailing PE of 13.92x is roughly 30% below the healthcare sector average of ~20x, and the PS ratio of 0.39 is well below historical norms. However, revenue growth of just 1.4% year-over-year and a net margin of 2.84% (down from 3.50%) highlight operational challenges. Free cash flow of $6.29 billion TTM is robust, and the 1.97% dividend yield with a 27% payout ratio offers income support. Analyst estimates for forward EPS of $47.89 suggest significant earnings growth from the trailing figure, but the forward PE of 14.14x being higher than the trailing PE indicates skepticism about near-term earnings. The implied upside to the average target is only 7.5%, limiting the risk-reward appeal.
The biggest risks that could invalidate this thesis include persistent margin compression due to elevated medical costs, regulatory changes affecting Medicare Advantage rates, and competitive pressures eroding market share. The rating would upgrade to Buy if the PE compresses below 12x or if revenue growth accelerates above 3% with margin stabilization. Conversely, a downgrade to Sell would occur if net margin falls below 2% or if revenue declines. Relative to its history and peers, ELV appears undervalued on a PE basis, but the discount is justified by its lower growth and profitability. The stock is fairly valued at current levels, with limited near-term catalysts to drive significant upside.
Sign up to view all
ELV 12-Month Price Forecast
Elevance Health presents a mixed picture: the stock is cheap relative to the sector and has strong analyst support, but its growth has stalled and margins are under pressure. The 2027 Medicare Advantage rate increase provides a potential catalyst, but it may already be priced in. The company's dual-engine model and robust free cash flow offer stability, yet the thin net margin of 2.84% leaves little room for error. I would upgrade to bullish if revenue growth accelerates above 3% and net margin stabilizes above 3%, or downgrade to bearish if margin falls below 2.5% or if regulatory headwinds intensify. Given the balanced risk-reward, a neutral stance is appropriate until clearer signs of operational improvement emerge.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Elevance Health, Inc.'s 12-month outlook, with a consensus price target around $450.05 and implied upside of +6.1% versus the current price.
Average Target
$450.05
0 analysts
Implied Upside
+6.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$393 - $492
Analyst target range
Wall Street coverage is robust, with 21 analysts providing recommendations. The consensus recommendation is 'Buy' with a recommendation mean of 1.77 (where 1 is Strong Buy and 5 is Strong Sell), indicating a bullish tilt. The average target price is $450.05, which implies an upside of approximately 7.5% from the current price of $418.72. This target is supported by an average estimated EPS of $47.89 for the forward year, suggesting analysts expect significant earnings growth from the trailing EPS of $0.07 (which appears to be a data anomaly) and the quarterly run-rate. The consensus is clearly optimistic, but the modest upside suggests the stock is already fairly valued near current levels. The target price range spans from a low of $393.00 to a high of $492.00, a spread of $99 or about 25% of the current price. The high target of $492 implies a scenario where Elevance successfully expands margins, benefits from favorable Medicare Advantage rate updates, and grows Carelon's profitability, potentially driving multiple expansion. The low target of $393 assumes margin compression persists, competitive pressures intensify, or medical cost trends worsen. Recent institutional ratings show a mix of Buy, Overweight, and Equal Weight ratings, with no recent downgrades, indicating stable sentiment. The wide target spread signals meaningful uncertainty around the company's earnings trajectory, but the concentration of analysts at Buy/Overweight suggests that the risk-reward is skewed to the upside for long-term investors.
Drowning in data?
Find the real signal!
Bulls vs Bears: ELV Investment Factors
The bull case for Elevance Health rests on its deep valuation discount (PE of 13.92x vs. sector ~20x), strong analyst support (average target $450.05), and the favorable 2027 Medicare Advantage rate update that improves revenue visibility. However, the bear case is equally compelling: revenue growth has stalled at 1.4%, margins are compressing (net margin down to 2.90% from 3.50%), and the stock is technically overextended near its 52-week high. The most critical tension is whether Elevance can stabilize and expand margins through operational efficiency and Carelon growth, or whether persistent medical cost pressures and government mix will continue to erode profitability. Given the modest 7.5% upside to analyst targets and the recent earnings decline, the bear evidence currently carries slightly more weight, but the valuation discount and sector tailwinds keep the risk-reward balanced. A resolution of the margin trajectory—either through cost controls or rate increases—will be the key driver of future performance.
Bullish
- Deep discount to sector valuation: ELV trades at a trailing PE of 13.92x and forward PE of 14.14x, roughly 30% below the healthcare sector average of ~20x. The PS ratio of 0.39 is also well below its historical average of 1.5-2.0x, suggesting the market is pricing in overly pessimistic expectations relative to the company's $50.5 billion quarterly revenue base.
- Strong analyst consensus with upside: 21 analysts cover ELV with a consensus 'Buy' rating (mean 1.77) and an average target price of $450.05, implying 7.5% upside from the current $418.72. The high target of $492 suggests a 17.5% upside if margin expansion materializes, and there have been no recent downgrades.
- Medicare Advantage rate tailwind: The larger-than-expected 2027 CMS Medicare Advantage payment increase announced in April 2026 boosted sector sentiment and revenue visibility. As a major player in government-sponsored programs, ELV directly benefits from this favorable rate environment, which supports future margin recovery.
- Robust free cash flow and capital returns: ELV generated $6.29 billion in trailing twelve-month free cash flow, with $4.10 billion in Q1 2026 alone. The company returned $373 million in dividends and $234 million in buybacks in Q2 2026, supported by a sustainable 27% payout ratio and a 1.97% dividend yield.
Bearish
- Stagnant revenue growth: Q2 2026 revenue grew only 1.4% year-over-year to $50.47 billion, well below the company's historical mid-single-digit trajectory. Revenue has plateaued around $50 billion for four consecutive quarters, indicating limited organic growth and increasing reliance on margin expansion or acquisitions.
- Margin compression and earnings decline: Q2 2026 net income fell to $1.46 billion from $1.74 billion a year earlier, with net margin contracting to 2.90% from 3.50%. Operating margin declined to 4.09% from 5.29%, reflecting elevated medical costs and a higher mix of lower-margin government business.
- Premium valuation relative to history: The current PE of 13.92x is near the lower end of its historical range (9.15x to 50.12x), but the forward PE of 14.14x is higher than the trailing PE, suggesting the market expects near-term earnings pressure. The PEG ratio of -5.70 is not meaningful due to distorted growth, highlighting earnings volatility.
- Thin margins limit error tolerance: A trailing net margin of 2.84% and operating margin of 4.09% leave little room for adverse medical cost trends or regulatory changes. Any unexpected spike in utilization or unfavorable rate adjustments could significantly impact profitability.
ELV Technical Analysis
Elevance Health is in a sustained uptrend, with the current price of $418.72 sitting just 4.0% below its 52-week high of $436.24 and a remarkable 52.4% above its 52-week low of $274.84. The stock has gained 32.97% over the past year, significantly outpacing the S&P 500's 16.22% advance, and is trading at approximately 90.7% of its 52-week range. This positioning signals strong momentum but also raises the risk of overextension, especially given the sharp run from the March 2026 lows near $284.79 to the July peak of $426.79. The 1-year relative strength of +16.75 percentage points versus SPY confirms persistent leadership, though the stock's beta of 0.696 implies it typically moves about 30% less than the broader market, making the magnitude of its outperformance even more notable.
Beta
0.70
0.70x market volatility
Max Drawdown
-26.5%
Largest decline past year
52-Week Range
$275-$436
Price range past year
Annual Return
+36.1%
Cumulative gain past year
| Period | ELV Return | S&P 500 |
|---|---|---|
| 1m | +6.0% | -2.0% |
| 3m | +6.6% | +1.4% |
| 6m | +43.8% | +15.0% |
| 1y | +36.1% | +15.7% |
| ytd | +19.8% | +11.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ELV Fundamental Analysis
Revenue growth has been steady but modest, with Q2 2026 revenue of $50.47 billion representing a 1.4% year-over-year increase from $49.78 billion in Q2 2025. Sequentially, revenue has hovered around $50 billion for four consecutive quarters, suggesting a plateau in top-line expansion. The Health Benefits segment remains the dominant contributor at $42.7 billion, while Carelon Services adds $19.2 billion before eliminations, highlighting a diversified but maturing revenue base. The 1.4% growth rate is below the company's historical mid-single-digit trajectory, implying that future earnings growth must come from margin expansion or capital deployment rather than robust organic revenue acceleration. Net income in Q2 2026 was $1.46 billion, down from $1.74 billion in Q2 2025, with a net margin of 2.90% versus 3.50% a year earlier. Gross margin stood at 89.1% in Q2 2026, but this figure is distorted by a reclassification of cost of revenue; the more comparable operating margin was 4.09%, down from 5.29% in Q2 2025. The compression reflects elevated medical costs and a higher mix of government-sponsored business, and the trailing twelve-month net margin of 2.84% remains thin for the managed care industry, where scale and pricing power are critical. The balance sheet shows a debt-to-equity ratio of 0.757 and a current ratio of 1.24, indicating moderate leverage and adequate short-term liquidity. Free cash flow on a trailing twelve-month basis was $6.29 billion, but quarterly FCF has been volatile, ranging from -$209 million in Q4 2025 to $4.10 billion in Q1 2026. Return on equity was 12.90%, while return on assets was 3.83%, reflecting the capital-intensive nature of the insurance business. The company returned cash to shareholders through $373 million in dividends and $234 million in buybacks in Q2 2026, but the dividend payout ratio of 27.0% and dividend yield of 1.97% suggest a balanced approach to capital allocation.
Quarterly Revenue
$50.5B
2026-06
Revenue YoY Growth
+1.4%
YoY Comparison
Gross Margin
89.1%
Latest Quarter
Free Cash Flow
$6.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ELV Overvalued?
Because Elevance Health is profitable with positive net income of $1.46 billion in Q2 2026, the PE ratio is the primary valuation metric. The trailing PE is 13.92x, while the forward PE is 14.14x, implying a slight premium for future earnings that is unusual given the expected EPS growth. The forward PE being marginally higher than the trailing PE suggests the market may be pricing in near-term earnings pressure or that the trailing figure benefits from one-time items. The PEG ratio of -5.70 is not meaningful due to negative or distorted growth rates, so the PE remains the most reliable gauge. Compared to the broader healthcare sector, where the average PE is often in the 18-22x range, Elevance trades at a significant discount. Its PE of 13.92x versus a sector average of approximately 20x represents a roughly 30% discount. This discount appears justified by the company's lower net margin of 2.84% and revenue growth of only 1.4%, which lag many peers. However, the discount may also reflect an opportunity if Elevance can stabilize margins and accelerate earnings. Historically, Elevance's PE has ranged from a low of 9.15x in Q1 2026 to a high of 50.12x in Q4 2024, with the current 13.92x sitting near the lower end of that band. The PS ratio of 0.39 is also well below its historical average of around 1.5-2.0x, suggesting the market is pricing in pessimistic expectations relative to the company's revenue base.
PE
13.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 9x~35x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.5x
Enterprise Value Multiple
Investment Risk Disclosure
Elevance Health faces significant financial and operational risks stemming from its thin margins and modest growth. The trailing net margin of 2.84% and operating margin of 4.09% leave minimal buffer against adverse medical cost trends, as evidenced by the Q2 2026 net income decline to $1.46 billion from $1.74 billion a year earlier. Revenue growth of just 1.4% year-over-year, with four consecutive quarters hovering around $50 billion, indicates a plateau that increases reliance on margin expansion or capital deployment for earnings growth. Additionally, the debt-to-equity ratio of 0.757 and current ratio of 1.24 reflect moderate leverage, but the capital-intensive nature of the insurance business (ROA of 3.83%) limits financial flexibility. The dividend payout ratio of 27% and $6.29 billion in trailing free cash flow provide some cushion, but quarterly FCF volatility (ranging from -$209 million to $4.10 billion) highlights cash flow unpredictability.
Market and competitive risks are pronounced given Elevance's premium valuation relative to its own history and the broader sector. The stock trades at a trailing PE of 13.92x, which is near the low end of its historical range (9.15x to 50.12x), but the forward PE of 14.14x suggests the market anticipates earnings pressure. With a beta of 0.696, ELV is less volatile than the market, but this also means it may underperform in strong bull markets. Competitive pressures in managed care, particularly in Medicare Advantage and Medicaid, could intensify if rivals gain share or if regulatory changes favor other insurers. The recent CMS rate increase for 2027 is a positive, but it may already be priced in, and any reversal or dilution of benefits could hurt sentiment. Sector rotation risk is also relevant, as healthcare stocks may fall out of favor if interest rates rise or if investors rotate to more cyclical sectors.
The worst-case scenario for Elevance involves a combination of margin compression, revenue stagnation, and multiple contraction. If medical costs continue to rise faster than premiums, net margin could fall below 2%, triggering earnings misses and analyst downgrades. A drop to the 52-week low of $274.84 would represent a 34.4% decline from the current price of $418.72. The analyst low target of $393 implies a 6.1% downside, but in a severe bear case, the stock could test its historical low PE of 9.15x, which on forward EPS of $47.89 would imply a price near $438—actually above current levels—but if earnings estimates are cut, the downside could be more severe. Realistically, a decline to the $300-$320 range (a 24-28% drop) is plausible if margin pressures persist and the company fails to deliver on growth initiatives. The max drawdown of -26.49% over the past year provides a reference for potential losses in a downturn.
FAQ
The most severe risk is margin compression: net margin fell to 2.90% in Q2 2026 from 3.50% a year earlier, and operating margin declined to 4.09% from 5.29%. If medical costs continue to rise faster than premiums, profitability could deteriorate further. Second, revenue growth is stagnant at 1.4% year-over-year, with revenue plateauing around $50 billion for four quarters, limiting earnings growth potential. Third, regulatory risk is significant, as changes to Medicare Advantage or Medicaid reimbursement rates could impact revenue and margins; the recent 2027 CMS rate increase is a positive, but future adjustments are uncertain. Fourth, competitive pressures in managed care could lead to membership losses, particularly in government programs. Finally, the stock is technically overextended near its 52-week high, and a beta of 0.696 means it may not fully participate in market rallies but could still decline in a downturn.
Our 12-month forecast for ELV includes three scenarios. The base case (55% probability) targets a range of $420-$450, assuming revenue growth remains around 1.5% and net margin stabilizes near 2.9%, with the stock trading near the analyst average target of $450. The bull case (25% probability) targets $450-$492, driven by successful margin expansion, favorable Medicare Advantage rates, and Carelon growth, pushing the PE toward 15-16x. The bear case (20% probability) targets $275-$393, assuming margin compression below 2.5%, regulatory headwinds, and multiple contraction to 10-11x. The most likely scenario is the base case, where the stock delivers modest returns with limited upside. Key assumptions include no major regulatory changes and stable medical cost trends. Investors should watch Q3 earnings for signs of margin stabilization.
ELV appears undervalued on a relative basis. Its trailing PE of 13.92x is significantly below the healthcare sector average of approximately 20x, and its PS ratio of 0.39 is well below its historical average of 1.5-2.0x. The forward PE of 14.14x is slightly higher than the trailing PE, suggesting the market expects near-term earnings pressure. Compared to its own history, the current PE is near the lower end of its range (9.15x to 50.12x), indicating that the market is pricing in pessimistic expectations. However, this discount is justified by ELV's lower net margin of 2.84% and revenue growth of only 1.4%, which lag many peers. The valuation implies the market expects continued margin compression and slow growth; if the company can stabilize margins, the multiple could expand toward the sector average, offering upside.
ELV presents a mixed case for investors. On the positive side, it trades at a trailing PE of 13.92x, roughly 30% below the healthcare sector average, and analysts have a consensus Buy rating with an average target of $450.05, implying 7.5% upside. The company also offers a 1.97% dividend yield and generates $6.29 billion in trailing free cash flow. However, revenue growth is stagnant at 1.4%, and net margin has compressed to 2.90% from 3.50% a year ago, raising concerns about earnings quality. The stock is also technically overextended, sitting just 4% below its 52-week high. For value-oriented investors with a long-term horizon, the discount may be attractive, but near-term upside appears limited. It could be a good buy on a pullback to the $390-$400 range, but at current levels, the risk-reward is balanced.
ELV is better suited for long-term investment rather than short-term trading. The company operates in a stable, regulated industry with a beta of 0.696, indicating lower volatility than the broader market. Its 1.97% dividend yield and consistent free cash flow generation ($6.29 billion TTM) make it attractive for income-focused investors. However, the stock has run up 32.97% over the past year and is trading near its 52-week high, suggesting limited short-term upside and potential for a pullback. Earnings visibility is moderate, with analysts estimating forward EPS of $47.89, but margin pressures create uncertainty. A minimum holding period of 2-3 years is recommended to allow for potential margin recovery and the realization of Medicare Advantage rate benefits. Short-term traders may find opportunities on dips, but the low beta and modest growth make it less ideal for momentum strategies.
